Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms COVADIS
Most Recent Events
- 07 Dec 2022 Status changed from recruiting to discontinued.
- 20 Jan 2022 New trial record
- 12 Jan 2022 Results (N=85) published in the Annals of the Rheumatic Diseases